UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Blood, 2012-05, Vol.119 (19), p.4375-4382

2012

Volltextzugriff (PDF)

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Supportive care in cancer, 2014-05, Vol.22 (5), p.1223-1231

2014

Volltextzugriff (PDF)

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

BMC cancer, 2020-09, Vol.20 (1), p.918-10, Article 918

2020

Volltextzugriff (PDF)

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.147-147, Article 147

2023

Volltextzugriff (PDF)

Ensuring Diversity and Inclusion in Clinical Development by Leveraging Community Oncology Centers

Journal of the National Comprehensive Cancer Network, 2023-08, Vol.21 (8), p.889-891

2023

Volltextzugriff (PDF)

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

Supportive care in cancer, 2018-11, Vol.26 (11), p.3773-3780

2018

Volltextzugriff (PDF)

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

BMC cancer, 2008-07, Vol.8 (1), p.195-195, Article 195

2008

Volltextzugriff (PDF)

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy

Journal of managed care & specialty pharmacy, 2018-10, Vol.24 (10), p.1019-1026

2018

Volltextzugriff (PDF)

Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s Lymphoma

Journal of clinical oncology, 2001-12, Vol.19 (23), p.4314-4321

2001

Volltextzugriff (PDF)

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States

Journal of managed care & specialty pharmacy, 2023-11, Vol.29 (11), p.1205-1218

2023

Volltextzugriff (PDF)

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Future oncology (London, England), 2024-01, Vol.20 (3), p.131-143

2024

Volltextzugriff (PDF)

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

Clinical lymphoma, myeloma and leukemia, 2018-02, Vol.18 (2), p.152-160

2018

Volltextzugriff (PDF)

Treating Multiple Myeloma Patients with Oral Therapies

Clinical lymphoma, myeloma and leukemia, 2017-05, Vol.17 (5), p.243-251

2017

Volltextzugriff (PDF)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

Clinical lymphoma, myeloma and leukemia, 2020-11, Vol.20 (11), p.e910-e925

2020

Volltextzugriff (PDF)

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

British journal of haematology, 2013-02, Vol.160 (3), p.321-330

2013

Volltextzugriff (PDF)

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

Annals of hematology, 2014, Vol.93 (1), p.89-98

2014

Volltextzugriff (PDF)

Treatment (tx) Patterns & Outcomes by Line of Therapy (LOT) in a Large United States (US) Cohort of Transplant-Ineligible Patients (pts) with Multiple Myeloma in the Era of Novel Agents

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e80-e81

2017

Volltextzugriff (PDF)

Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use

The oncologist (Dayton, Ohio), 2007-04, Vol.12 (4), p.484-494

2007

Volltextzugriff (PDF)

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

American journal of hematology, 2009-10, Vol.84 (10), p.657-660

2009

Volltextzugriff (PDF)

Association Between Treatment Regimen Type in Second-Line Therapy (2LT) and Duration of Therapy (DOT) & Time To Next Treatment (TTNT) in a United States (US) Relapsed/Refractory Multiple Myeloma (RRMM) Cohort

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e81-e82

2017

Volltextzugriff (PDF)

Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies

Transfusion (Philadelphia, Pa.), 2009-04, Vol.49 (4), p.786-796

2009

Volltextzugriff (PDF)

P-325 In-Class Transition From Parenteral Bortezomib (V) to Oral Ixazomib in Newly Diagnosed Multiple Myeloma (NDMM): Updated 3-Year PFS Analysis of US MM-6 Overall and by Patient (pt) Subgroups of Interest

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S222-S222

2024

Volltextzugriff (PDF)

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Blood, 2023-11, Vol.142 (Supplement 1), p.6677-6677

2023

Volltextzugriff (PDF)

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Blood, 2023-11, Vol.142 (Supplement 1), p.4764-4764

2023

Volltextzugriff (PDF)

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Blood, 2009-11, Vol.114 (22), p.127-127

2009

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Englisch
(115)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(52)
Humans
(45)
Female
(26)
Adult
(25)
Middle Aged
(24)
Biological And Medical Sciences
(23)
Hematology
(20)
Male
(20)
Medical Sciences
(19)
Oncology
(17)
Aged
(13)
Animals
(11)
Immunology
(10)
Multiple Myeloma - Drug Therapy
(9)
Aged, 80 And Over
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Adolescent
(7)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Ensuring Diversity and Inclusion in Clinical Development by Leveraging Community Oncology Centers

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy

Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s Lymphoma

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

Treating Multiple Myeloma Patients with Oral Therapies

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

Treatment (tx) Patterns & Outcomes by Line of Therapy (LOT) in a Large United States (US) Cohort of Transplant-Ineligible Patients (pts) with Multiple Myeloma in the Era of Novel Agents

Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

Association Between Treatment Regimen Type in Second-Line Therapy (2LT) and Duration of Therapy (DOT) & Time To Next Treatment (TTNT) in a United States (US) Relapsed/Refractory Multiple Myeloma (RRMM) Cohort

Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies

P-325 In-Class Transition From Parenteral Bortezomib (V) to Oral Ixazomib in Newly Diagnosed Multiple Myeloma (NDMM): Updated 3-Year PFS Analysis of US MM-6 Overall and by Patient (pt) Subgroups of Interest

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Suchergebnisse filtern